Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody
Positive Top-Line Data From Phase II FIGHT Trial
A potential first-in-class FGFR2b-targeted monoclonal antibody, bemarituzumab, has shown top-line benefits in the Phase II FIGHT study in advanced gastric or gastroesophageal junction cancers.
